))
Syntis Bio: Solutions to Unlock Obesity and Metabolic Disorders
Fetch error
Hmmm there seems to be a problem fetching this series right now.
Last successful fetch was on October 30, 2025 17:16 (
What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.
Manage episode 417617266 series 3554501
内容由Teymour Boutros-Ghali and Felicia Hsu, Teymour Boutros-Ghali, and Felicia Hsu提供。所有播客内容（包括剧集、图形和播客描述）均由 Teymour Boutros-Ghali and Felicia Hsu, Teymour Boutros-Ghali, and Felicia Hsu 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品，您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
In this episode of Just Bold Enough, Teymour and Felicia discuss an innovative biotech company, Syntis Bio, and how it will disrupt obesity treatment. Syntis has developed a gastric bypass-in-a-pill that blocks the absorption of glucose in the small intestine. This simple, yet clever solution could revolutionize the treatment of obesity and have a significant impact on the pharmaceutical industry by improving the delivery of other drugs. The team is led by experienced CEO, Rahul Dhanda, who is now leading the company into human clinical trials. The company also prioritizes health equity by aiming to disrupt the high cost of obesity treatments such as Ozempic and make it more accessible to those who need it.
Story Notes:
- Addressing the Obesity Challenge
- Navigating the Regulatory Landscape
- The Potential Impact on the Pharmaceutical Industry
To learn more, visit:
https://boldcapitalpartners.com/
5集单集
分享
